| Name | Title | Contact Details |
|---|
Codex DNA is home to Gibson Assembly, and pioneering synthetic DNA/gene synthesis hardware, including the BioXp, the world’s first DNA printer. Our mission is to empower scientific researchers in both academic and commercial settings with the materials...
We are dedicated to developing and commercializing effective and broadly applicable interventions for food allergy. Food allergy is a disease of the immune system that is triggered by an exceptionally broad range of commonly allergenic foods such as cow’s milk, eggs, tree nuts, peanuts, shellfish and even sesame. In a perfect world, the human immune system would adapt to all foods. However, in tens of millions of people, the immune system wrongly recognizes some food proteins as harmful and does not adapt. We envision a world where, with help from oral immunotherapy, the immune system can adapt to nearly all food allergens. And we built our inspiration into our name—Alladapt. Alladapt was co-founded in 2018 in Palo Alto, California, by allergist and protein biochemist Kari Nadeau, MD, PhD, and biotechnology entrepreneur, Ashley Dombkowski, PhD. Academic clinical research conducted by Dr. Nadeau has demonstrated that a food allergic immune system in an individual person can be receptive to remodeling by gradually increasing exposure, under tightly controlled clinical supervision, to the proteins that activate the inappropriate cascade of reactions. This work, combined with research illuminating disease mechanisms and pathways, led the founders to envision a biopharmaceutical intervention capable of addressing food allergy provoked by a wide-ranging set of antigens. Food allergy is a serious disease, with potentially life-threatening consequences. The disease has grown dramatically in recent years and now affects more than 6 million children¹ and 26 million adults² in the United States alone. Importantly, about half of people with food allergy are reactive to multiple foods, which further increases the risk of anaphylaxis due to accidental ingestion. The chronic, unpredictable components of this disease can elevate anxiety in patients and their families, and place extreme limitations on their lives. It is our goal to help patients experience more of life’s magical moments with less fear and greater confidence.
Allied Safety Associates is a West Columbia, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Aruvant`s mission is to bring hope to patients living with rare diseases by developing life changing and potentially curative gene therapies, with a near-term focus on sickle cell disease. Aruvant is a part of the Roivant family of companies. We have a talented team with extensive experience in the development, manufacturing and commercialization of gene therapy products. We have an active research program with a lead product candidate in development for individuals suffering from sickle cell disease (SCD). Our lead product candidate, ARU-1801, an investigational lentiviral gene therapy, is currently in a clinical trial as a potential one-time curative treatment for SCD. Preliminary clinical data from the ongoing Phase 1/2 study demonstrated durable efficacy in reducing the negative impacts of SCD. We are preparing for the launch of our pivotal clinical trial in SCD. We continue to look for new people to add to our talented team.